Skip to main content

Table 2 Studies included in the analysis and main findings

From: Glycoprotein IIb/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: a systematic review, meta-analysis, and meta-regression

Study Design No. patients GPI (n) Age (GPI vs Standard care) Outcomes
Giri et al. [11] Nonrandomized, prospective, observational
(1995–1999)
114 54 66 ± 14 vs 67 ± 13 • GPI significantly improved final TIMI flow.
• At 30-day follow-up, the composite event rate of death, myocardial reinfarction, and target vessel revascularization were better in the GPI group (31% vs 63%; P = 0.002).
• Lower mortality (22% vs 44%; p = 0.02) and recurrent infarction rates (0% vs 10%; p = 0.05) in the GPI group.
• Combination of abciximab and stents was synergistic and resulted in improvement of all components of the composite end point.
Chan et al. [12] Nonrandomized, prospective, observational
(1993–2000)
96 45 67 ± 11 vs 64 ± 14 vs 63 ± 16 vs 68 ± 9
(Stent+abciximab vs stent only vs PCI + abciximab vs PCI alone)
• 2.5 years of follow-up, the mortality rates for stent plus abciximab, stent only, PCI plus abciximab, and PCI alone were 33%, 43%, 61%, and 68% (P = 0.028).
• Stent and abciximab resulted in higher TIMI 3 flow rates (85% vs 65%, P = 0.048).
• A trend of mortality benefit with abciximab was seen at 30 months (HR 0.74, 95% CI 0.36–1.11, P = 0.11).
Antoniucci et al. [13] Nonrandomized, prospective, observational
(1999–2001)
77 44 66 ± 12 vs 71 ± 12 • 1-month overall mortality rate was lower in the abciximab (18% vs 42%, P < 0.020).
• No differences between groups in reinfarction and target vessel revascularization rates.
• Multivariate analysis showed that abciximab therapy was the only variable independently related to 1-month mortality (OR 0.36; 95% CI 0.15–0.86, P < 0.021).
PRAGUE-7
Tousek et al. [14]
Randomized control trial
(2006–2009)
80 40 64 ± 14 vs 68 ± 11 • The 30-day combined outcome of death/reinfarction/stroke/new severe renal failure occurred in 42.5% in the group randomized to abciximab vs 27.5% in the standard therapy group (P = 0.24).
• No differences were found in TIMI-flow after PCI or major bleeding.
Bernat et al. [15] Nonrandomized, observational
(2006–2010)
179 80 NA • The use of GPI (HR 0.63, 95% CI 0.40–0.96, P = 0.032) was associated with a better outcome at a-year in multivariable analysis.
Felice et al. [16] Nonrandomized, observational
(2002–2011)
410 287 67 ± 12 vs 73 ± 12 • No difference at a 1-year survival rates (42.8% vs 51.6%, P = 0.56) in patients treated without vs. with abciximab.
• Age, oro-tracheal intubation, post-PCI TIMI flow grade 0–1 but not abciximab use (HR, 1.08; 95% CI 0.70–1.60, P = 0.60) were independent predictors of death at 1-year follow-up.
Kanic et al. [17] (2009–2014) 261 170 66.7 ± 12.5 vs 64.9 ± 12.9 • All-cause mortality was similar between groups (46.5% vs 54.9%) at 30 days; (53.5% vs. 61.1%) at 1 year.
• The adjunctive usage of GPI (OR 0.41; 95%CI 0.20–0.84; P = 0.015), and novel P2Y12 inhibitors were associated with a better 30-day survival.
• Better 1-year survival was independently predicted by GPI (HR 0.62; 95%CI 0.39–0.97; P = 0.037), novel P2Y12 inhibitors, age, left main PCI, TIMI 0/1 pre-PCI, and major bleeding.
  1. GPI glycoprotein IIb/IIIa inhibitors, TIMI thrombolysis in myocardial infarction, PCI percutaneous coronary intervention, NA not applicable, HR hazard ratio, OR odds ratio, CI confidence intervals